Want to see JP:7774 full AI Analyst Report?
7774 Stock Chart & Stats
¥575.00
¥0.00(0.00%)
At close: 4:00 PM EST
¥575.00
¥0.00(0.00%)
Day’s Range― - ―
52-Week Range¥448.00 - ¥898.00
Previous CloseN/A
Volume17.40K
Average Volume (3M)122.44K
Market Cap
¥35.70B
Enterprise Value¥21.99K
Total Cash (Recent Filing)¥3.35B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta1.15
Next Earnings
Nov 04, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-10.84
Shares Outstanding40,610,200
10 Day Avg. Volume92,480
30 Day Avg. Volume122,443
Financial Highlights & Ratios
PEG Ratio-0.18
Price to Book (P/B)4.75
Price to Sales (P/S)11.09
P/FCF Ratio-43.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)27.9
Revenue Forecast (FY)¥5.05B
Bulls Say, Bears Say
Bulls Say
Debt-Free Balance SheetEffectively no debt materially reduces solvency and refinancing risk. This gives J-TEC greater flexibility to fund regenerative medicine operations and absorb volatility without the fixed-interest burden faced by more leveraged peers.
Integrated Regenerative Medicine ModelAn integrated model spanning development, controlled manufacturing, and commercialization can retain more value from proprietary tissue-engineering capabilities. It also supports consistent quality control across the product lifecycle.
Substantial Equity CushionA substantial equity base provides a financial cushion while the company works to restore profitability and cash generation. Although equity has declined over time, its current scale still supports continued operations and strategic investment.
Bears Say
Persistent Revenue ContractionBack-to-back annual revenue declines after the 2024 rebound indicate weak commercial momentum and limited near-term visibility. Sustained contraction could reduce operating leverage and make it harder to spread manufacturing and development costs.
Deepening Net LossesThe sharp swing from profit to increasingly large losses signals deteriorating earnings quality and weak scale efficiency. Without a durable improvement in revenue or costs, accumulated losses could continue reducing equity and strategic flexibility.
Accelerating Cash BurnNegative operating and free cash flow indicate that current activities are consuming, rather than generating, cash. If the trend persists, J-TEC may need to draw down its equity resources or seek external funding to sustain development and production.
Japan Tissue Engineering Co., Ltd. News
7774 FAQ
What was Japan Tissue Engineering Co., Ltd.’s price range in the past 12 months?
Japan Tissue Engineering Co., Ltd. lowest stock price was ¥448.00 and its highest was ¥898.00 in the past 12 months.
What is Japan Tissue Engineering Co., Ltd.’s market cap?
Japan Tissue Engineering Co., Ltd.’s market cap is ¥35.70B.
When is Japan Tissue Engineering Co., Ltd.’s upcoming earnings report date?
Japan Tissue Engineering Co., Ltd.’s upcoming earnings report date is Nov 04, 2026 which is in 60 days.
How were Japan Tissue Engineering Co., Ltd.’s earnings last quarter?
Japan Tissue Engineering Co., Ltd. released its earnings results on Jul 30, 2026. The company reported ¥1.29 earnings per share for the quarter.
Is Japan Tissue Engineering Co., Ltd. overvalued?
According to Wall Street analysts Japan Tissue Engineering Co., Ltd.’s price is currently Overvalued.
Does Japan Tissue Engineering Co., Ltd. pay dividends?
Japan Tissue Engineering Co., Ltd. does not currently pay dividends.
What is Japan Tissue Engineering Co., Ltd.’s EPS estimate?
Japan Tissue Engineering Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Japan Tissue Engineering Co., Ltd. have?
Japan Tissue Engineering Co., Ltd. has 40,610,200 shares outstanding.
What happened to Japan Tissue Engineering Co., Ltd.’s price movement after its last earnings report?
Japan Tissue Engineering Co., Ltd. reported an EPS of ¥1.29 in its last earnings report. Following the earnings report the stock price went up 9.091%.
Which hedge fund is a major shareholder of Japan Tissue Engineering Co., Ltd.?
Currently, no hedge funds are holding shares in JP:7774
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Japan Tissue Engineering Co., Ltd.
Japan Tissue Engineering Co., Ltd. operates within the regenerative medicine sector in Japan. The company's activities are organized into three core divisions: Regenerative Medicine Product, Regenerative Medicine Outsourcing, and Research and Development Support. It manufactures and delivers autologous cultured tissues, such as epidermis, cartilage, corneal epithelium, and oral mucosal epithelium, to medical institutions for therapeutic applications. The firm also produces other advanced tissue-engineered medical products. Furthermore, Japan Tissue Engineering is involved in the research and development of three-dimensional human cultured tissue models, which are utilized in the development of external-use cosmetics and drugs, as well as for scientific investigations concerning skin and corneal tissues. Additionally, the company provides comprehensive contract development and manufacturing services for regenerative medicine. Established in 1999, Japan Tissue Engineering Co., Ltd. is based in Gamagori, Japan, and functions as a subsidiary of Teijin Limited.